Bellus Health (OTCMKTS:BLUSF) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Friday.
Bellus Health (OTCMKTS:BLUSF) traded down $0.01 during trading on Friday, hitting $0.32. The company had a trading volume of 14,000 shares, compared to its average volume of 15,257. Bellus Health has a fifty-two week low of $0.18 and a fifty-two week high of $0.36.
ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/03/bellus-health-blusf-stock-rating-lowered-by-valuengine.html.
BELLUS Health Inc is a Canada-based biopharmaceutical development company. The Company’s pipeline of projects includes the BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs. BLU-5937 is a potent, selective, orally bio-available small molecule antagonist of the P2X3 receptor, a clinically validated target for chronic cough.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Bellus Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellus Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.